Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhanced diagnostic tools for visceral leishmaniasis using kinase based antigens in Brazilian human and canine samples.

Scientific reports·2026
Same author

Decoding the cross-immune pressure: Dengue's role in SARS-CoV-2 evolution.

Computational and structural biotechnology journal·2025
Same author

Functional and phenotypic analysis of CD4 T cell dynamics in peripheral blood of human visceral leishmaniasis patients confers increased frequencies of CD25 expressing regulatory T cells that contribute to disease pathogenesis.

Frontiers in immunology·2025
Same author

A Dual-Action Liposome-Peptide Formulation Synergistically Counteracts A Gain-of-Function p53 Mutant.

bioRxiv : the preprint server for biology·2025
Same author

A dual-action liposome-peptide formulation synergistically counteracts a gain-of-function p53 mutant.

Journal of liposome research·2025
Same author

Evaluation of <i>Leishmania</i> homolog of activated C kinase (LACK) of <i>Leishmania donovani</i> in comparison to glycoprotein 63 as a vaccine candidate against visceral leishmaniasis.

Microbiology spectrum·2025

Related Experiment Video

Updated: Apr 29, 2026

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice
06:57

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice

Published on: February 20, 2020

7.7K

Genetically modified organisms and visceral leishmaniasis.

Rudra Chhajer1, Nahid Ali1

  • 1Infectious Diseases and Immunology Division, Council of Scientific and Industrial Research-Indian Institute of Chemical Biology , Kolkata , India.

Frontiers in Immunology
|May 27, 2014
PubMed
Summary

Developing effective vaccines against leishmaniasis is crucial. This review examines genetically modified organisms for parasitic disease vaccination, focusing on their potential application in combating leishmaniasis.

Keywords:
Leishmaniagenetically modified parasitesimmunologyvaccinesvisceral leishmaniasis

More Related Videos

Development of Leishmania Species Strains with Constitutive Expression of eGFP
10:03

Development of Leishmania Species Strains with Constitutive Expression of eGFP

Published on: April 21, 2023

1.5K
In vivo Imaging of Transgenic Leishmania Parasites in a Live Host
09:53

In vivo Imaging of Transgenic Leishmania Parasites in a Live Host

Published on: July 27, 2010

15.5K

Related Experiment Videos

Last Updated: Apr 29, 2026

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice
06:57

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice

Published on: February 20, 2020

7.7K
Development of Leishmania Species Strains with Constitutive Expression of eGFP
10:03

Development of Leishmania Species Strains with Constitutive Expression of eGFP

Published on: April 21, 2023

1.5K
In vivo Imaging of Transgenic Leishmania Parasites in a Live Host
09:53

In vivo Imaging of Transgenic Leishmania Parasites in a Live Host

Published on: July 27, 2010

15.5K

Area of Science:

  • Parasitology
  • Vaccinology
  • Genetics

Background:

  • Leishmaniases are significant protozoan diseases, second only to malaria in global parasite-related deaths.
  • Visceral leishmaniasis (kala-azar) is the most severe and potentially fatal form if left untreated.
  • Vaccination is a primary strategy for infectious disease prevention, building on successes like smallpox eradication.

Purpose of the Study:

  • To review the successes and failures of using genetically modified organisms (GMOs) in vaccines against major parasitic diseases.
  • To evaluate the applicability of these GMO-based vaccination strategies for leishmaniasis.

Main Methods:

  • Review of existing literature on GMOs in parasitic disease vaccine development.
  • Analysis of different vaccine approaches, including killed parasite, subunit, DNA, live recombinant carrier, and live attenuated parasite vaccines.
  • Evaluation of gene candidates for live attenuated vaccine development.

Main Results:

  • Various vaccine strategies against leishmaniases are in development, including live attenuated parasite vaccines.
  • Promising results have been observed in some research areas.
  • Further evaluation of potential genes is necessary for developing effective live attenuated vaccine candidates.

Conclusions:

  • Genetically modified organisms hold potential for developing novel vaccines against leishmaniasis.
  • Continued research is needed to identify and validate optimal gene targets for live attenuated vaccines.
  • Successful GMO-based vaccines could significantly impact the control of leishmaniases.